Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis

References

• Hellstrom-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology. 2008;1:52–59.
   Google Scholar
• Patnaik MM, Tefferi A. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 update on diagnosis, risk-stratification, and management". Am J Hematol. 2019;94(4):475–488.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica. 2012;97(7):1036–1041.
   PubMed Web of Science ®Google Scholar
• Clara JA, Sallman DA, Padron E. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Cancer Biol Med. 2016;13(3):360–372.
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Lasho TL, Finke CM, et al. Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. Am J Hematol. 2016;91(5):492–498.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Cazzola M. Refractory anemia with ring sideroblasts. Best Pract Res Clin Haematol. 2013;26(4):377–385.
   PubMed Web of Science ®Google Scholar
• Antelo G, Mangaonkar AA, Coltro G, et al. Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Br J Haematol. 2020;189(3):e104–e108.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes. Ann Oncol. 2016;27(1):62–68.
   PubMed Web of Science ®Google Scholar
• Talati C, Sallman D, List A. Lenalidomide: myelodysplastic syndromes with del(5q) and beyond. Semin Hematol. 2017;54(3):159–166.
   PubMed Web of Science ®Google Scholar
• Nichele I, Ruggeri M, Rodeghiero F. Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation. Am J Hematol. 2015;90(8):E148–E149.
   PubMed Web of Science ®Google Scholar
• Huls G, Mulder AB, Rosati S, et al. Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis. Blood. 2010;116(2):180–182.
   PubMed Web of Science ®Google Scholar
• Nicolosi M, Mudireddy M, Vallapureddy R, et al. Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). Am J Hematol. 2018;93(1):E27–E30.
   PubMed Web of Science ®Google Scholar
• Taylor G, Culligan D, Vickers MA. Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia. Case Rep Hematol. 2013;2013:718480.
   PubMedGoogle Scholar
• Keen R, Pantin J, Savage N, et al. Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations. Hematol Rep. 2016;8(4):6592.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
   PubMed Web of Science ®Google Scholar
• Pradhan S. Refractory anemia with ring sideroblasts and thrombocytosis. Blood Res. 2017;52(1):8.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Morita Y, Maeda Y, Yamaguchi T, et al. Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): a prospective single-arm phase 2 trial. Cancer Sci. 2018;109(10):3209–3215.
   PubMed Web of Science ®Google Scholar
• Santini V. Azacitidine in lower-risk myelodysplastic syndromes. Leuk Res. 2009; 33(Suppl 2):S22–S26.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86–93.
   PubMed Web of Science ®Google Scholar
• Santini V, Almeida A, Giagounidis A, et al. Randomized phase III study of lenalidomide versus placebo in RBC Transfusion-Dependent patients with Lower-Risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol. 2016;34(25):2988–2996.
   PubMed Web of Science ®Google Scholar
• Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood. 2015;126(21):2366–2369.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020;382(2):140–151.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Al-Kali A, Begna KH, et al. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J. 2016;6(3):e405.
   PubMedGoogle Scholar